HRP20110776T1 - Stabilizirani farmaceutski sastavi koji sadrže fesoterodin - Google Patents
Stabilizirani farmaceutski sastavi koji sadrže fesoterodin Download PDFInfo
- Publication number
- HRP20110776T1 HRP20110776T1 HR20110776T HRP20110776T HRP20110776T1 HR P20110776 T1 HRP20110776 T1 HR P20110776T1 HR 20110776 T HR20110776 T HR 20110776T HR P20110776 T HRP20110776 T HR P20110776T HR P20110776 T1 HRP20110776 T1 HR P20110776T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- composition according
- fesoterodine
- weight
- xylitol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 26
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 title claims abstract 20
- 229960002978 fesoterodine Drugs 0.000 title claims abstract 19
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract 12
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract 10
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract 10
- 239000000811 xylitol Substances 0.000 claims abstract 10
- 235000010447 xylitol Nutrition 0.000 claims abstract 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract 10
- 229960002675 xylitol Drugs 0.000 claims abstract 10
- 239000003381 stabilizer Substances 0.000 claims abstract 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract 7
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 239000000600 sorbitol Substances 0.000 claims abstract 7
- 235000010356 sorbitol Nutrition 0.000 claims abstract 7
- 229920001100 Polydextrose Polymers 0.000 claims abstract 6
- 239000001259 polydextrose Substances 0.000 claims abstract 6
- 229940035035 polydextrose Drugs 0.000 claims abstract 6
- 235000013856 polydextrose Nutrition 0.000 claims abstract 6
- 229960002920 sorbitol Drugs 0.000 claims abstract 6
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims abstract 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract 5
- 239000008121 dextrose Substances 0.000 claims abstract 5
- 239000000905 isomalt Substances 0.000 claims abstract 5
- 235000010439 isomalt Nutrition 0.000 claims abstract 5
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims abstract 5
- 239000012453 solvate Substances 0.000 claims abstract 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- 238000005469 granulation Methods 0.000 claims 6
- 230000003179 granulation Effects 0.000 claims 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- GNWCZBXSKIIURR-UHFFFAOYSA-N (2-docosanoyloxy-3-hydroxypropyl) docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCCCCCC GNWCZBXSKIIURR-UHFFFAOYSA-N 0.000 claims 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 238000013265 extended release Methods 0.000 claims 3
- 239000000454 talc Substances 0.000 claims 3
- 229910052623 talc Inorganic materials 0.000 claims 3
- 206010020853 Hypertonic bladder Diseases 0.000 claims 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 2
- 238000007906 compression Methods 0.000 claims 2
- 230000006835 compression Effects 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 208000020629 overactive bladder Diseases 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 150000003627 tricarboxylic acid derivatives Chemical class 0.000 claims 2
- 238000005550 wet granulation Methods 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 230000001186 cumulative effect Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06011943 | 2006-06-09 | ||
| EP06011942 | 2006-06-09 | ||
| EP06011941 | 2006-06-09 | ||
| PCT/EP2007/055582 WO2007141298A1 (en) | 2006-06-09 | 2007-06-06 | Stabilized pharmaceutical compositions comprising fesoterodine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110776T1 true HRP20110776T1 (hr) | 2011-11-30 |
Family
ID=38521333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110776T HRP20110776T1 (hr) | 2006-06-09 | 2011-10-25 | Stabilizirani farmaceutski sastavi koji sadrže fesoterodin |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP2029134B1 (xx) |
| JP (2) | JP4743321B2 (xx) |
| KR (1) | KR101316773B1 (xx) |
| CN (1) | CN101466371B (xx) |
| AP (1) | AP2416A (xx) |
| AR (1) | AR061289A1 (xx) |
| AT (1) | ATE517619T1 (xx) |
| AU (1) | AU2007255408B2 (xx) |
| BR (1) | BRPI0712865B1 (xx) |
| CA (1) | CA2652712C (xx) |
| CR (1) | CR10494A (xx) |
| CU (1) | CU23850B1 (xx) |
| CY (1) | CY1111934T1 (xx) |
| DK (1) | DK2029134T3 (xx) |
| EA (1) | EA015909B9 (xx) |
| EC (1) | ECSP089010A (xx) |
| ES (1) | ES2370943T3 (xx) |
| GT (1) | GT200800276A (xx) |
| HK (1) | HK1128626A1 (xx) |
| HR (1) | HRP20110776T1 (xx) |
| IL (2) | IL195732A (xx) |
| MA (1) | MA30504B1 (xx) |
| MX (1) | MX2008015736A (xx) |
| MY (1) | MY146574A (xx) |
| NI (1) | NI200800318A (xx) |
| NL (1) | NL2000690C2 (xx) |
| NO (1) | NO341980B1 (xx) |
| NZ (1) | NZ572616A (xx) |
| PE (2) | PE20120476A1 (xx) |
| PL (1) | PL2029134T3 (xx) |
| PT (1) | PT2029134E (xx) |
| RS (1) | RS51973B (xx) |
| SI (1) | SI2029134T1 (xx) |
| TN (1) | TNSN08505A1 (xx) |
| TW (2) | TWI520735B (xx) |
| UY (1) | UY30394A1 (xx) |
| WO (1) | WO2007141298A1 (xx) |
| ZA (1) | ZA200806411B (xx) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110086103A1 (en) * | 2008-04-04 | 2011-04-14 | Actavis Group Ptc Ehf | Novel mandelate salt of fesoterodine |
| IT1392082B1 (it) * | 2008-12-10 | 2012-02-09 | Chemi Spa | Nuove forme solide della fesoterodina fumarato |
| PL2416761T3 (pl) | 2009-05-11 | 2015-07-31 | Ratiopharm Gmbh | Desfezoterodyna w postaci soli kwasu winowego |
| EP2316432A1 (de) | 2009-10-30 | 2011-05-04 | ratiopharm GmbH | Zusammensetzung enthaltend Fesoterodin und Ballaststoffe |
| US20130172411A1 (en) * | 2010-03-22 | 2013-07-04 | Cadila Healthcare Limited | Stable pharmaceutical compositions comprising fesoterodine |
| TWI590821B (zh) * | 2011-01-18 | 2017-07-11 | 輝瑞有限公司 | 固體分子分散液 |
| EP2508175A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof |
| EP2508173A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Stabilized pharmaceutical composition comprising fesoterodine |
| US20140199401A1 (en) * | 2011-07-04 | 2014-07-17 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of fesoterodine |
| EP2780317A2 (en) * | 2012-05-18 | 2014-09-24 | Alembic Pharmaceuticals Limited | The novel reference markers for fesoterodine fumarate |
| WO2014006636A2 (en) * | 2012-07-02 | 2014-01-09 | Hetero Research Foundation | Stable compositions of fesoterodine |
| PL2914255T3 (pl) | 2012-11-02 | 2022-01-03 | Murray & Poole Enterprises, Ltd. | Leczenie incydentów sercowo-naczyniowych lub zapobieganie im poprzez podawanie kolchicyny |
| MA38576B2 (fr) | 2013-11-26 | 2020-02-28 | Murray And Poole Enterprises Ltd | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières |
| CZ2014400A3 (cs) | 2014-06-09 | 2015-12-16 | Zentiva, K.S. | Stabilizovaná formulace fesoterodinu |
| CN105687154A (zh) * | 2014-11-27 | 2016-06-22 | 合肥信风科技开发有限公司 | 含非索罗定的药用组合物及其制备方法 |
| WO2019011393A1 (en) | 2017-07-12 | 2019-01-17 | Rontis Hellas S.A. | EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF |
| TR201721437A2 (tr) * | 2017-12-25 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari |
| WO2019132832A1 (en) * | 2017-12-25 | 2019-07-04 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Tablet compositions of fesoterodine fumarate |
| KR102018495B1 (ko) * | 2018-03-13 | 2019-09-05 | 충북대학교 산학협력단 | 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법 |
| CA3094551C (en) | 2018-04-26 | 2024-01-02 | Rontis Hellas S.A. | Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof |
| CN110151720B (zh) * | 2019-05-09 | 2019-12-17 | 合肥信风科技开发有限公司 | 含非索罗定的药用组合物及其制备方法 |
| WO2023145486A1 (ja) * | 2022-01-28 | 2023-08-03 | 沢井製薬株式会社 | フェソテロジンフマル酸塩含有製剤の製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010034552A (ko) * | 1998-03-03 | 2001-04-25 | 요시히코 시오노 | 포스포리파제 저해제인 소듐[[3-(2-아미노-1,2-디옥소에틸)-2-에틸-1-(페닐메틸)-1ｈ-인돌-4-일]옥시]아세테이트를 포함하는 약학적 조성물 |
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| DE19955190A1 (de) * | 1999-11-16 | 2001-06-21 | Sanol Arznei Schwarz Gmbh | Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen |
| DE10224107A1 (de) * | 2002-05-29 | 2003-12-11 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz |
| DE10315878B4 (de) * | 2003-04-08 | 2009-06-04 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung |
-
2007
- 2007-06-06 AT AT07729956T patent/ATE517619T1/de active
- 2007-06-06 MX MX2008015736A patent/MX2008015736A/es active IP Right Grant
- 2007-06-06 MY MYPI20084409A patent/MY146574A/en unknown
- 2007-06-06 SI SI200730758T patent/SI2029134T1/sl unknown
- 2007-06-06 CN CN2007800212925A patent/CN101466371B/zh not_active Expired - Fee Related
- 2007-06-06 PL PL07729956T patent/PL2029134T3/pl unknown
- 2007-06-06 TW TW102118368A patent/TWI520735B/zh not_active IP Right Cessation
- 2007-06-06 CA CA2652712A patent/CA2652712C/en active Active
- 2007-06-06 RS RS20110469A patent/RS51973B/en unknown
- 2007-06-06 UY UY30394A patent/UY30394A1/es active IP Right Grant
- 2007-06-06 EP EP07729956A patent/EP2029134B1/en active Active
- 2007-06-06 PE PE2011001996A patent/PE20120476A1/es not_active Application Discontinuation
- 2007-06-06 ES ES07729956T patent/ES2370943T3/es active Active
- 2007-06-06 PE PE2007000695A patent/PE20080331A1/es active IP Right Grant
- 2007-06-06 KR KR1020087027920A patent/KR101316773B1/ko active IP Right Grant
- 2007-06-06 AP AP2008004673A patent/AP2416A/xx active
- 2007-06-06 NZ NZ572616A patent/NZ572616A/en not_active IP Right Cessation
- 2007-06-06 AU AU2007255408A patent/AU2007255408B2/en not_active Ceased
- 2007-06-06 EA EA200802444A patent/EA015909B9/ru active Protection Beyond IP Right Term
- 2007-06-06 DK DK07729956.8T patent/DK2029134T3/da active
- 2007-06-06 PT PT07729956T patent/PT2029134E/pt unknown
- 2007-06-06 JP JP2009513691A patent/JP4743321B2/ja active Active
- 2007-06-06 TW TW096120242A patent/TWI397409B/zh not_active IP Right Cessation
- 2007-06-06 BR BRPI0712865-7A patent/BRPI0712865B1/pt not_active IP Right Cessation
- 2007-06-06 WO PCT/EP2007/055582 patent/WO2007141298A1/en active Application Filing
- 2007-06-08 NL NL2000690A patent/NL2000690C2/nl active Search and Examination
- 2007-06-08 AR ARP070102485A patent/AR061289A1/es not_active Application Discontinuation
-
2008
- 2008-07-21 ZA ZA200806411A patent/ZA200806411B/xx unknown
- 2008-12-01 NI NI200800318A patent/NI200800318A/es unknown
- 2008-12-04 IL IL195732A patent/IL195732A/en not_active IP Right Cessation
- 2008-12-04 GT GT200800276A patent/GT200800276A/es unknown
- 2008-12-05 TN TNP2008000505A patent/TNSN08505A1/fr unknown
- 2008-12-08 MA MA31460A patent/MA30504B1/fr unknown
- 2008-12-08 CU CU2008000235A patent/CU23850B1/es active IP Right Grant
- 2008-12-11 CR CR10494A patent/CR10494A/es unknown
- 2008-12-24 EC EC2008009010A patent/ECSP089010A/es unknown
-
2009
- 2009-01-09 NO NO20090141A patent/NO341980B1/no unknown
- 2009-07-27 HK HK09106893.6A patent/HK1128626A1/xx not_active IP Right Cessation
-
2011
- 2011-02-28 JP JP2011041842A patent/JP4781489B2/ja active Active
- 2011-10-17 CY CY20111100983T patent/CY1111934T1/el unknown
- 2011-10-25 HR HR20110776T patent/HRP20110776T1/hr unknown
-
2012
- 2012-07-05 IL IL220800A patent/IL220800A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110776T1 (hr) | Stabilizirani farmaceutski sastavi koji sadrže fesoterodin | |
| JP2009539802A5 (xx) | ||
| TW200936183A (en) | Pharmaceutical compositions | |
| HRP20100615T1 (hr) | Farmaceutski sastavi koji sadrže imatinib i usporivač otpuštanja | |
| CA2611114A1 (en) | An entacapone-containing oral dosage form | |
| NO20130366A1 (no) | Bruk av bindemidler for fremstilling av lagringsstabile formuleringer | |
| IL195572A (en) | Suspended release formulations | |
| CN102512393A (zh) | 一种托伐普坦的口腔崩解片 | |
| JP2014224079A (ja) | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 | |
| WO2009034540A1 (en) | Pharmaceutical composition of sevelamer | |
| Idu | Effect of the molecular size of carboxymethylcellulose and some polymers on the sustained release of theophylline from a hydrophilic matrix | |
| HRP20130225T1 (hr) | Formulacija s odgođenim otpuštanjem koja sadrži 3-(2-dimetilaminometilcikloheksil) fenol | |
| TW201031410A (en) | Pharmaceutical compositions with superior product performance and patient compliance | |
| AU2006274565B2 (en) | Novel controlled release compositions of selective serotonin reuptake inhibitors | |
| CN103877056B (zh) | 一种氯吡格雷片及其制备方法 | |
| CN102349876B (zh) | 一种治疗胃溃疡和十二指肠溃疡的药物及其配制方法 | |
| RU2010153977A (ru) | Композиции, содержащие euphorbia prostrata, и способ их получения | |
| CN106562968B (zh) | 包含盐酸坦洛辛和琥珀酸索利那新的药物组合物 | |
| CN101103964A (zh) | 一种含有非洛地平的缓释制剂及其制备方法 | |
| CA2785687A1 (en) | Composition containing fesoterodine and fibers | |
| AU2014368504B2 (en) | Gastro-retentive oral pharmaceutical compositions | |
| KR101482315B1 (ko) | 난용성 약물을 함유하는 팽윤성 위체류 정제 조성물 | |
| JP2003073270A (ja) | 安定性および溶出性の良好なプラバスタチンナトリウム錠 | |
| RU2584653C2 (ru) | Фармацевтическая композиция с пролонгированным высвобождением с антипсихотической активностью и способы её получения | |
| KR102018495B1 (ko) | 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법 |